Rating History for Jazz Pharmaceuticals (JAZZ) by UBS
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 5/19/2026 | Ashwani Verma | Upgrade | Buy (Neutral) |
307.00 (188.00) |
228.77 (254.28) |
11.15% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 5/19/2026 | Ashwani Verma | Upgrade | Buy (Neutral) |
307.00 (188.00) |
228.77 (254.28) |
11.15% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||